CK2: A key player in cancer biology

被引:285
|
作者
Trembley, J. H. [1 ,2 ]
Wang, G. [1 ,2 ]
Unger, G. [3 ]
Slaton, J. [4 ,5 ,6 ]
Ahmed, K. [1 ,2 ,5 ,6 ]
机构
[1] Vet Affairs Med Ctr, Cellular & Mol Biochem Res Lab 151, Minneapolis, MN 55417 USA
[2] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[3] GeneSegues, Chaska, MN USA
[4] Vet Affairs Med Ctr, Urol Serv, Minneapolis, MN USA
[5] Univ Minnesota, Dept Urol, Minneapolis, MN USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
关键词
CK2; casein kinase 2; CKII; cancer; dysregulation; upregulation; prognostic marker; therapeutic target; nanoparticle; nanocapsule; PROTEIN-KINASE CK2; FACTOR-KAPPA-B; PHOSPHORYLATION-REGULATED CLEAVAGE; LIGAND-INDUCED APOPTOSIS; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR PTEN; HUMAN PROSTATE-CANCER; RNA-POLYMERASE-I; NUCLEAR-MATRIX; CASEIN KINASE-2;
D O I
10.1007/s00018-009-9154-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target. (Part of Multi-author Review)
引用
收藏
页码:1858 / 1867
页数:10
相关论文
共 50 条
  • [1] Protein Kinase CK2 in Health and DiseaseCK2: A key player in cancer biology
    J. H. Trembley
    G. Wang
    G. Unger
    J. Slaton
    K. Ahmed
    Cellular and Molecular Life Sciences, 2009, 66 : 1858 - 1867
  • [2] Interaction between CK2α and CK2β, the Subunits of Protein Kinase CK2: Thermodynamic Contributions of Key Residues on the CK2α Surface
    Raaf, Jennifer
    Bischoff, Nils
    Klopffleisch, Karsten
    Brunstein, Elena
    Olsen, Birgitte B.
    Vilk, Greg
    Litchfield, David W.
    Issinger, Olaf-Georg
    Niefind, Karsten
    BIOCHEMISTRY, 2011, 50 (04) : 512 - 522
  • [3] CK2: a key regulator of thrombopoiesis
    Vainchenker, William
    Raslova, Hana
    BLOOD, 2017, 130 (25) : 2695 - 2697
  • [4] Design of CK2β-Mimicking Peptides as Tools To Study the CK2α/CK2β Interaction in Cancer Cells
    Lindenblatt, Dirk
    Horn, Mareike
    Goetz, Claudia
    Niefind, Karsten
    Neundorf, Ines
    Pietsch, Markus
    CHEMMEDCHEM, 2019, 14 (08) : 833 - 841
  • [5] Emergence of protein kinase CK2 as a key target in cancer therapy
    Trembley, Janeen H.
    Chen, Zhong
    Unger, Gretchen
    Slaton, Joel
    Kren, Betsy T.
    Van Waes, Carter
    Ahmed, Khalil
    BIOFACTORS, 2010, 36 (03) : 187 - 195
  • [6] Mining CK2 in Cancer
    Ortega, Charina E.
    Seidner, Yoshua
    Dominguez, Isabel
    PLOS ONE, 2014, 9 (12):
  • [7] CK2 and the Hallmarks of Cancer
    Firnau, May-Britt
    Brieger, Angela
    BIOMEDICINES, 2022, 10 (08)
  • [8] The interaction of CK2α and CK2β, the subunits of protein kinase CK2, requires CK2β in a preformed conformation and is enthalpically driven
    Raaf, Jennifer
    Brunstein, Elena
    Issinger, Olaf-Georg
    Niefind, Karsten
    PROTEIN SCIENCE, 2008, 17 (12) : 2180 - 2186
  • [9] Targeting CK2 for cancer therapy
    Ahmad, KA
    Wang, GX
    Slaton, J
    Unger, G
    Ahmed, K
    ANTI-CANCER DRUGS, 2005, 16 (10) : 1037 - 1043
  • [10] PROTEIN KINASE CK2 IS A KEY REGULATOR OF ERYTHROPOIESIS
    Tubi, L. Quotti
    Nunes, S. Canovas
    Mandato, E.
    Pizzi, M.
    Vitulo, N.
    D'agnolo, M.
    Colombatti, R.
    Martella, M.
    Boaro, M. P.
    Breatta, E. Doriguzzi
    Fregnani, A.
    Spinello, Z.
    Nabergoj, M.
    Filhol, O.
    Boldyreff, B.
    Albiero, M.
    Fadini, G. P.
    Gurrieri, C.
    Vianello, F.
    Semenzato, G.
    Manni, S.
    Trentin, L.
    Piazza, F.
    HAEMATOLOGICA, 2024, 109 : 48 - 48